EDSA

Edesa Biotech, Inc.

4.71 USD
-0.27 (-5.42%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Edesa Biotech, Inc. stock is up 1.51% since 30 days ago. The next earnings date is May 9, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 30.77% of the previous 12 February’s closed higher than January. 100% of analysts rate it a buy.

About Edesa Biotech, Inc.

Edesa Biotech, Inc. engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients. EB01, a topical treatment for chronic allergic contact dermatitis, is also in Phase 2B clinical study.